The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Long-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis
Open accessAbstract
BACKGROUND: Mutations in RPE65 cause Leber's congenital amaurosis, a progressive retinal degenerative disease that severely impairs sight in children. Gene therapy can result in modest improvements in night vision, but knowledge of its efficacy in humans is limited. METHODS: We performed a phase 1-2 open-label trial involving 12 participants to evaluate the safety and efficacy of gene therapy with a recombinant adeno-associated virus 2/2 (rAAV2/2) vector carrying the RPE65 complementary DNA, and measured visual function over the course of 3 years. Four participants were administered a lower dose of the vector, and 8 were administered a higher dose. In a parallel study in dogs, we investigated the relationship among vector dose, visual function, and electroretinography (ERG) findings. RESULTS: Improvements in retinal sensitivity were evident, to varying extents, in six participants for up to 3 years, peaking at 6 to 12 months after treatment and then declining. No associated improvement in retinal function was detected by means of ERG. Three participants had intraocular inflammation, and two had clinically significant deterioration of visual acuity. The reduction in central retinal thickness varied among participants. In dogs, RPE65 gene therapy with the same vector at lower doses improved vision-guided behavior, but only higher doses resulted in improvements in retinal function that were detectable with the use of ERG. CONCLUSIONS: Gene therapy with rAAV2/2 RPE65 vector improved retinal sensitivity, albeit modestly and temporarily. Comparison with the results obtained in the dog model indicates that there is a species difference in the amount of RPE65 required to drive the visual cycle and that the demand for RPE65 in affected persons was not met to the extent required for a durable, robust effect. (Funded by the National Institute for Health Research and others; ClinicalTrials.gov number, NCT00643747.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ocular AAV therapies leading to a permanent reduction in visual acuity following intraocular inflammation (9–11)”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AAV dose-dependent intraocular inflammation and a few instances of persistent loss of visual acuity have been independently reported in clinical trials following subretinal AAV administration despite prophylactic immunosuppression (9–11).”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the phase 1/2 dose-escalation trials for RPE65-associated LCA, choroideremia, and retinitis pigmentosa GTPase regulator (RPGR)-associated X-linked retinitis pigmentosa, patients receiving higher doses of AAV have presented with various signs of retinal inflammation, including vitritis, retinitis, and choroiditis,2,6,7 implicating the presence of a cell-mediated immune response.”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite the perceived low immunogenicity of AAV and relative immune privilege of the intraocular environment,8 dose-dependent retinal inflammation, or gene therapy-associated uveitis (GTAU), has been observed in many retinal gene therapy trials, which limits the vector dose and therapeutic efficacy.”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite a 28-day oral corticosteroid therapy started 2 days before the first IVT, a regimen similar to that provided in several other clinical studies using IVT or sub-retinal AAV-based gene therapies,41–45 70.7% of lenadogene nolparvovec-treated eyes developed some degree of intraocular inflammation versus 10.2% of placebo-treated eyes.”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [45]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is clinically important as intraocular inflammation could lead to irreversible loss of retinal cells, deterioration of visual function and reduced durability of treatment effect associated with a costly one-off treatment.”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The intraocular inflammation is dose-dependent and can sometimes last for months or even years following treatment, leading to irreversible retinal structural damage and reduced visual function if uncontrolled (Bainbridge et al., 2015).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The intraocular inflammation is dose-dependent and can sometimes last for months or even years following treatment, leading to irreversible retinal structural damage and reduced visual function if uncontrolled (Bainbridge et al., 2015).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably, one participant developed anterior uveitis at 2 weeks, followed by CRA and reduced visual acuity by 6 months.”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two participants developed optic disc swelling, retinal vascular tortuosity/sheathing and mild vitritis.”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Three out of eight participants who received the higher dose of vector (1 × 10 12 vg/eye) but none in the lower dose cohort (1 × 10 11 vg/eye) developed intraocular inflammation despite prophylactic peri-operative immunosuppression.”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, GTAU is often diagnosed shortly after the withdrawal of systemic immunosuppression prophy laxis (Dimopoulos et al., 2018) or when the dose reaches around 15 -20 mg for slower tapers, and sometimes several weeks to months after vector administration (Bainbridge et al., 2015).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although adeno-associated viral (AAV) vector-mediated retinal gene therapies have demonstrated efficacy”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [2]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The intraocular inflammation is dose-dependent and can sometimes last for months or even years following treatment, leading to irreversible retinal structural damage and reduced visual function if uncontrolled (Bainbridge et al., 2015).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredIn the citing paper
“In phase I/II clinical trials for RPE65-LCA at University College London (ClinicalTrials.gov: NCT00643747), ocular inflammation was noted following SRI of 1 × 1012 vg of AAV2-RPE65.71,99”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [99]
In the citing paper
“subfoveal viral gene therapy has been associated with various adverse effects, such as RPE alterations, retinal thinning, foveal morphological changes, vision loss, and the variable duration of clinical effects [281,294,296,297,298].”
From Bruch’s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration (2023) · cites this paper as [296]
In the citing paper
“Dose-dependent immune responses have also been observed, with high doses potentially leading to persistent inflammation and clinically significant vision loss in patients receiving high-dose AAV2 vector-based subretinal RPE65 therapy [296].”
From Bruch’s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration (2023) · cites this paper as [296]
In the citing paper
“However, some adverse events linked to the glucocorticoids themselves have already been described in retinal rAAV trials which point out the need for other alternatives to mitigate the inflammation [37].”
From Risk mitigation of immunogenicity: a key to personalized retinal gene therapy (2021) · cites this paper as [37]
In the citing paper
“The results showed that retinal sensitivity was improved; however, the final transgene expression in the participants from the high dose group was adversely affected by ocular inflammation or immune responses [48].”
From Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy (2022) · cites this paper as [48]
In the citing paper
“Nonetheless, inflammatory reactions to gene therapy in the eye have led to permanent vision loss for some patients7–9.”
From Investigation of Cas9 Antibodies in the Human Eye (2022) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hartong, D. T., Berson, E. L., & Dryja, T. P. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69740-7 · Cited by 2,924
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Self-citationStatistics Notes: Measurement error
Bland, J. M., & Altman, D. G. (1996) · BMJ · doi:10.1136/bmj.313.7059.744 · Cited by 1,084
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
Leber congenital amaurosis: Genes, proteins and disease mechanisms
den Hollander, A. I., Roepman, R., Koenekoop, R. K., & Cremers, F. P. M. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.05.003 · Cited by 811
Cideciyan, A. V., Alemán, T. S., Boye, S. L., Schwartz, S., Kaushal, S., Román, A. J., Pang, J., Sumaroka, A., Windsor, E. A. M., Wilson, J. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807027105 · Cited by 674
Jacobson, S. G. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.298 · Cited by 639
Flagged first, then by citations
Research works printed but not linked: 3
- Poehner WJ, 2000, Mol Vis, 6, 192
- Geller SF, 2001, Invest Ophthalmol Vis Sci, 42, 1363
- 10.1056/NEJMoa1412965 · DOI
Cited by
Sorted by citations
Items 101–200 of 743
Humoral immune response after intravitreal but not after subretinal AAV8 in primates and patients
Reichel, F. F., Peters, T., Wilhelm, B., Biel, M., Ueffing, M., Wissinger, B., Bartz-Schmidt, K. U., Klein, R., Michalakis, S., Fischer, M. D., et al. (2018) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22494 · Cited by 86
Halting progressive neurodegeneration in advanced retinitis pigmentosa
Koch, S., Tsai, Y.-T., Duong, J., Wu, W.-H., Hsu, C., Wu, W., Bonet‐Ponce, L., Lin, C., & Tsang, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82462 · Cited by 85
Clinical Perspectives and Trends: Microperimetry as a Trial Endpoint in Retinal Disease
Yang, Y., & Dunbar, H. (2021) · Ophthalmologica · doi:10.1159/000515148 · Cited by 93
Cone-Specific Promoters for Gene Therapy of Achromatopsia and Other Retinal Diseases
Ye, G., Budzynski, E., Sonnentag, P. J., Nork, T. M., Sheibani, N., Gürel, Z., Boye, S. L., Peterson, J. J., Boye, S. L., Hauswirth, W. W., et al. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.130 · Cited by 85
Large Animal Models of Inherited Retinal Degenerations: A Review
Winkler, P. A., Occelli, L. M., & Petersen‐Jones, S. M. (2020) · Cells · doi:10.3390/cells9040882 · Cited by 85
Self-citationChen, G., Ma, B., Wang, Y., & Gong, S. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b03496 · Cited by 80
Liver induced transgene tolerance with AAV vectors
Keeler, G. D., Markusic, D. M., & Hoffman, B. E. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.12.002 · Cited by 81
Gonzalez-Cordero, A., Goh, D., Kruczek, K., Naeem, A., Fernando, M., kleine Holthaus, S.-M., Takaaki, M., Blackford, S. J. I., Kloc, M., Agundez, L., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.027 · Cited by 77
Self-citationAdvances in gene therapy for diseases of the eye
Petit, L., Khanna, H., & Punzo, C. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.040 · Cited by 82
Chen, H. Y., Kaya, K. D., Dong, L., & Swaroop, A. (2016) · Europe PMC (PubMed Central) · Cited by 80
Optogenetic Peripheral Nerve Immunogenicity
Maimon, B. E., Diaz, M., Revol, E. C. M., Schneider, A. M., Leaker, B. D., Varela, C. E., Srinivasan, S. S., Weber, M. B., & Herr, H. (2018) · Scientific Reports · doi:10.1038/s41598-018-32075-0 · Cited by 77
Gene therapy for inherited retinal diseases
Nuzbrokh, Y., Ragi, S. D., & Tsang, S. H. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4726 · Cited by 79
Pennesi, M. E., Yang, P., Birch, D. G., Weng, C. Y., Moore, A. T., Iannaccone, A., Comander, J. I., Jayasundera, T., Chulay, J., Chulay, J., et al. (2022) · Ophthalmology Retina · doi:10.1016/j.oret.2022.06.013 · Cited by 71
Self-citationHighly Efficient Delivery of Adeno-Associated Viral Vectors to the Primate Retina
Boye, S. L., Alexander, J. J., Witherspoon, C. D., Boye, S. L., Peterson, J. J., Clark, M. E., Sandefer, K. J., Girkin, C. A., Hauswirth, W. W., & Gamlin, P. D. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.085 · Cited by 81
Gene Therapy for Human Sensorineural Hearing Loss
Ren, Y., Landegger, L. D., & Stanković, K. M. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00323 · Cited by 78
Chowdhury, E. A., Meno‐Tetang, G. M. L., Chang, H. Y., Wu, S., Huang, H. W., Jamier, T., Chandran, J. S., & Shah, D. K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.017 · Cited by 80
Varela, M. D., de Guimarães, T. A. C., Georgiou, M., & Michaelides, M. (2021) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-318483 · Cited by 74
Self-citationKalloniatis, M., Nivison‐Smith, L., Chua, J., Acosta, M. L., & Fletcher, E. L. (2015) · Experimental Eye Research · doi:10.1016/j.exer.2015.10.019 · Cited by 78
Ayton, L. N., Rizzo, J. F., Bailey, I. L., Colenbrander, A., Dagnelie, G., Geruschat, D. R., Hessburg, P. C., McCarthy, C. D., Petoe, M. A., Rubin, G. S., et al. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.8.25 · Cited by 75
Self-citationLong-term Structural Outcomes of Late-stage RPE65 Gene Therapy
Gardiner, K. L., Cideciyan, A. V., Swider, M., Dufour, V. L., Sumaroka, A., Komáromy, A. M., Hauswirth, W. W., Iwabe, S., Jacobson, S. G., Beltran, W. A., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.08.013 · Cited by 67
CRISPR-Cas9 genome engineering: Treating inherited retinal degeneration
Burnight, E. R., Giacalone, J. C., Cooke, J. A., Thompson, J. R., Bohrer, L. R., Chirco, K. R., Drack, A. V., Fingert, J. H., Worthington, K. S., Wiley, L. A., et al. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.03.003 · Cited by 79
Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A., Sahel, J., & Dalkara, D. (2016) · Biotechnology and Bioengineering · doi:10.1002/bit.26031 · Cited by 71
Voretigene Neparvovec in Retinal Diseases: A Review of the Current Clinical Evidence
Gao, J., Hussain, R. M., & Weng, C. Y. (2020) · Clinical ophthalmology · doi:10.2147/opth.s231804 · Cited by 80
Adeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog
Rapti, K., & Grimm, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.753467 · Cited by 73
Rakoczy, E. P., Magno, A. L., Lai, C.-M., Pierce, C. M., Degli-Esposti, M. A., Blumenkranz, M. S., & Constable, I. J. (2019) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2019.03.006 · Cited by 70
Gene therapy for inherited retinal disease: Long-term durability of effect
Leroy, B. P., Fischer, M. D., Flannery, J. G., MacLaren, R. E., Dalkara, D., Scholl, H. P. N., Chung, D. C., Spera, C., Viriato, D., & Banhazi, J. (2023) · Ophthalmic Research · doi:10.1159/000526317 · Cited by 70
Ding, W. Y., Kuzmuk, V., Hunter, S., Lay, A. C., Hayes, B., Beesley, M., Rollason, R., Hurcombe, J., Barrington, F., Masson, C., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abc8226 · Cited by 75
Morelli, K. H., Griffin, L. B., Pyne, N. K., Wallace, L. M., Fowler, A. M., Oprescu, S. N., Takase, R., Wei, N., Meyer‐Schuman, R., Mellacheruvu, D., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci130600 · Cited by 70
Optogenetic Gene Therapy for the Degenerate Retina: Recent Advances
McClements, M. E., Staurenghi, F., MacLaren, R. E., & Cehajic‐Kapetanovic, J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.570909 · Cited by 73
Nonsyndromic Retinitis Pigmentosa Overview
Fahim, A. T., Daiger, S. P., & Weleber, R. G. (2017) · Europe PMC (PubMed Central) · Cited by 70
Self-citationKumaran, N., Michaelides, M., Smith, A. J., Ali, R. R., & Bainbridge, J. W. (2018) · British Medical Bulletin · doi:10.1093/bmb/ldy005 · Cited by 74
Self-citationLeber Congenital Amaurosis (LCA): Potential for Improvement of Vision
Cideciyan, A. V., & Jacobson, S. G. (2019) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.19-26672 · Cited by 69
Britten‐Jones, A. C., Jin, R., Gocuk, S. A., Cichello, E., O’Hare, F., Hickey, D. G., Edwards, T. L., & Ayton, L. N. (2021) · Genetics in Medicine · doi:10.1016/j.gim.2021.10.013 · Cited by 67
Gene editing and its applications in biomedicine
Li, G., Li, X., Zhuang, S., Wang, L., Zhu, Y., Chen, Y., Sun, W. C., Wu, Z., Zhou, Z. L., Chen, J., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-021-2057-0 · Cited by 66
Results at 5 Years After Gene Therapy for RPE65-Deficient Retinal Dystrophy
Pennesi, M. E., Weleber, R. G., Yang, P. G., Whitebirch, C., Thean, B., Flotte, T. R., Humphries, M. R., Chegarnov, E. N., Beasley, K. N., Stout, J. T., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.014 · Cited by 66
Self-citationGene Therapy in Inherited Retinal Diseases: An Update on Current State of the Art
Amato, A., Arrigo, A., Aragona, E., Manitto, M. P., Saladino, A., Bandello, F. M., & Parodi, M. B. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.750586 · Cited by 68
Adeno-Associated Viral Gene Therapy for Inherited Retinal Disease
Ong, T., Pennesi, M. E., Birch, D. G., Lam, B. L., & Tsang, S. H. (2019) · Pharmaceutical Research · doi:10.1007/s11095-018-2564-5 · Cited by 66
Carvalho, L. S., Xiao, R., Wassmer, S. J., Langsdorf, A., Zinn, E., Pacouret, S., Shah, S., Comander, J. I., Kim, L. A., Lim, L., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.154 · Cited by 63
Choice of vector and surgical approach enables efficient cochlear gene transfer in nonhuman primate
Andrés‐Mateos, E., Landegger, L. D., Unzu, C., Phillips, J., Lin, B. M., Dewyer, N. A., Sanmiguel, J. C., Nicolaou, F., Valero, M. D., Bourdeu, K. I., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28969-3 · Cited by 64
Wang, X., Yu, C., Tzekov, R. T., Zhu, Y., & Li, W. (2020) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-020-1304-1 · Cited by 68
Motas, S., Haurigot, V., Garcia, M., Marcó, S., Ribera, A., Roca, C., Sánchez, X., Sánchez, V., Molas, M., Bertolin, J., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.86696 · Cited by 63
Han, I. C., Cheng, J. L., Burnight, E. R., Ralston, C. L., Fick, J. L., Thomsen, G. J., Tovar, E. F., Russell, S. R., Sohn, E. H., Mullins, R. F., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.043 · Cited by 60
Choroideremia: from genetic and clinical phenotyping to gene therapy and future treatments
Mitsios, A., Dubis, A. M., & Moosajee, M. (2018) · Therapeutic Advances in Ophthalmology · doi:10.1177/2515841418817490 · Cited by 62
Neurostimulation for Stroke Rehabilitation
Ting, W. K., Fadul, F. A.-R., Fecteau, S., & Éthier, C. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.649459 · Cited by 65
Visual cycle proteins: Structure, function, and roles in human retinal disease
Tsin, A. T. C., Betts-Obregon, B. S., & Grigsby, J. G. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.aw118.003228 · Cited by 69
Adeno-Associated Virus Vectors: Principles, Practices, and Prospects in Gene Therapy
Zwi‐Dantsis, L., Mohamed, S., Massaro, G., & Moeendarbary, E. (2025) · Viruses · doi:10.3390/v17020239 · Cited by 68
Neuroprotection in Glaucoma: Towards Clinical Trials and Precision Medicine
Khatib, T. Z., & Martin, K. R. G. (2019) · Current Eye Research · doi:10.1080/02713683.2019.1663385 · Cited by 61
Ciulla, T. A., Hussain, R. M., Berrocal, A. M., & Nagiel, A. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1740676 · Cited by 59
Patrício, M. I., Barnard, A. R., Orlans, H. O., McClements, M. E., & MacLaren, R. E. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2016.12.006 · Cited by 59
Retinal Degeneration and Regeneration—Lessons From Fishes and Amphibians
Ail, D., & Perron, M. (2017) · Current Pathobiology Reports · doi:10.1007/s40139-017-0127-9 · Cited by 59
Jacobson, S. G., Cideciyan, A. V., Sumaroka, A., Román, A. J., Charng, J., Lu, M., Choi, W., Sheplock, R., Świder, M., Kosyk, M. S., et al. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-21560 · Cited by 58
Advancements in the design and scalable production of viral gene transfer vectors
Sharon, D. M., & Kamen, A. (2017) · Biotechnology and Bioengineering · doi:10.1002/bit.26461 · Cited by 66
The CRB1 Complex: Following the Trail of Crumbs to a Feasible Gene Therapy Strategy
Quinn, P. M. J., Pellissier, L. P., & Wijnholds, J. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00175 · Cited by 59
Petersen‐Jones, S. M., Occelli, L. M., Winkler, P. A., Lee, W., Sparrow, J. R., Tsukikawa, M., Boye, S. L., Chiodo, V. A., Capasso, J. E., Bećirović, E., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci95161 · Cited by 56
Self-citationRamlogan‐Steel, C. A., Murali, A., Andrzejewski, S., Dhungel, B. P., Steel, J. C., & Layton, C. J. (2018) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.13416 · Cited by 60
Wu, Y., Wan, X., Zhao, D., Chen, X., Wang, Y., Tang, X., Li, J., Li, S., Sun, X., Bi, C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40655-6 · Cited by 59
What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans?Preprint
Herati, R. S., & Wherry, E. J. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a031583 · Cited by 57
Paying for future success in gene therapy
Orkin, S. H., & Reilly, P. R. (2016) · Science · doi:10.1126/science.aaf4770 · Cited by 59
Fahim, A. T., Sullivan, L. S., Bowne, S. J., Webb-Jones, K., Wheaton, D. K., Khan, N. W., Heckenlively, J. R., Jayasundera, T., Branham, K. E. H., Andrews, C., et al. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.11.010 · Cited by 56
Development of New Strategies Using Extracellular Vesicles Loaded with Exogenous Nucleic Acid
Orefice, N. S. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12080705 · Cited by 56
Hohman, T. C. (2016) · Handbook of Experimental Pharmacology · doi:10.1007/164_2016_91 · Cited by 56
The clinical features of retinal disease due to a dominant mutation in RPE65.
Hull, S., Mukherjee, R., Holder, G. E., Moore, A. T., & Webster, A. R. (2016) · Europe PMC (PubMed Central) · Cited by 55
Self-citationYiu, G. C., Tieu, E., Nguyen, A. T., Wong, B. M., & Smit‐McBride, Z. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-20296 · Cited by 55
Zhang, W., Kim, S. M., Wang, W., Cai, C., Feng, Y., Kong, W., & Lin, X. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00221 · Cited by 55
Quantitative progression of retinitis pigmentosa by optical coherence tomography angiography
Jauregui, R., Park, K. S., Duong, J., Mahajan, V. B., & Tsang, S. H. (2018) · Scientific Reports · doi:10.1038/s41598-018-31488-1 · Cited by 55
Humoral immune responses to AAV gene therapy in the ocular compartment
Whitehead, M., Osborne, A., Yu‐Wai‐Man, P., & Martin, K. (2021) · Biological Reviews · doi:10.1111/brv.12718 · Cited by 52
Subretinal therapy: technological solutions to surgical and immunological challenges
Ladha, R., Caspers, L. E., Willermain, F., & de Smet, M. D. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.846782 · Cited by 54
Precision genome editing in the eye
Suh, S., Choi, E. H., Raguram, A., Liu, D. R., & Palczewski, K. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2210104119 · Cited by 56
Gene Therapy in a Large Animal Model of PDE6A-Retinitis Pigmentosa
Mowat, F. M., Occelli, L. M., Bartoe, J. T., Gervais, K. J., Bruewer, A. R., Querubin, J. R., Dinculescu, A., Boye, S. L., Hauswirth, W. W., & Petersen‐Jones, S. M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00342 · Cited by 54
Self-citationHost immune responses after suprachoroidal delivery of AAV8 in nonhuman primate eyes
Chung, S. H., Mollhoff, I. N., Mishra, A., Sin, T.-N., Ngo, T., Ciulla, T., Sieving, P., Thomasy, S. M., & Yiu, G. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.281 · Cited by 57
Ye, G.-J., Budzynski, E., Sonnentag, P., Miller, P. E., Sharma, A. K., Ver Hoeve, J. N., Howard, K., Knop, D. R., Neuringer, M., McGill, T., et al. (2015) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2015.076 · Cited by 53
Ren, D., Fisson, S., Dalkara, D., & Ail, D. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091973 · Cited by 52
The Future Looks Brighter After 25 Years of Retinal Gene Therapy
Auricchio, A., Smith, A. J., & Ali, R. R. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.164 · Cited by 53
Self-citationIt is time for a moonshot to find “Cures” for diabetic retinal disease
Levine, S. R., Sapieha, P. S., Dutta, S., Sun, J. K., & Gardner, T. W. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101051 · Cited by 53
Has retinal gene therapy come of age? From bench to bedside and back to bench
Trapani, I., & Auricchio, A. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz130 · Cited by 55
Towards the Clinical Application of Gene Therapy for Genetic Inner Ear Diseases
Lahlou, G., Calvet, C., Giorgi, M., Lecomte, M.-J., & Safieddine, S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12031046 · Cited by 57
Protecting retinal ganglion cells
Khatib, T. Z., & Martin, K. R. G. (2017) · Eye · doi:10.1038/eye.2016.299 · Cited by 51
Chandler, L. C., Barnard, A. R., Caddy, S. L., Patrício, M. I., McClements, M. E., Fu, H., Rada, C., MacLaren, R. E., & Xue, K. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.05.012 · Cited by 50
Muhuri, M., Zhan, W., Maeda, Y., Li, J., Lotun, A., Chen, J., Sylvia, K., Dasgupta, I., Arjomandnejad, M., Nixon, T., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.674242 · Cited by 50
Non-viral therapeutic approaches to ocular diseases: An overview and future directions
Zulliger, R., Conley, S. M., & Naash, M. I. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.007 · Cited by 50
BEST1: the Best Target for Gene and Cell Therapies
Yang, T., Justus, S., Li, Y., & Tsang, S. H. (2015) · Molecular Therapy · doi:10.1038/mt.2015.177 · Cited by 51
Lyons, L. A., Creighton, E. K., Alhaddad, H., Beale, H. C., Grahn, R. A., Rah, H., Maggs, D. J., Helps, C. R., & Gandolfi, B. (2016) · BMC Genomics · doi:10.1186/s12864-016-2595-4 · Cited by 50
Chandler, L., Yusuf, I., McClements, M., Barnard, A., MacLaren, R., & Xue, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144972 · Cited by 49
Pathways and disease-causing alterations in visual chromophore production for vertebrate vision
Kiser, P. D., & Palczewski, K. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.014405 · Cited by 50
Gene therapy in retinal diseases: A review
Dhurandhar, D., Sahoo, N. K., Mariappan, I., & Narayanan, R. (2021) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_3117_20 · Cited by 52
Historic Overview of Genetic Engineering Technologies for Human Gene Therapy
Tamura, R., & Toda, M. (2020) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2020-0049 · Cited by 52
Novack, G. D., & Robin, A. L. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.634 · Cited by 48
HDAC inhibition ameliorates cone survival in retinitis pigmentosa mice
Samardzija, M., Corna, A., Gomez-Sintes, R., Jarboui, M. A., Armento, A., Roger, J. E., Petridou, E., Haq, W., Paquet-Durand, F., Zrenner, E., et al. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00653-3 · Cited by 48
García, H., Serafin, A. S., Silbermann, F., Porée, E., Viau, A., Mahaut, C., Billot, K., Birgy, É., Garfa‐Traoré, M., Roy, S., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2115960119 · Cited by 47
Genome editing in the treatment of ocular diseases
Choi, E. H., Suh, S., Sears, A. E., Hołubowicz, R., KEDHAR, S. R., Browne, A., & Palczewski, K. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01057-2 · Cited by 51
AAV-mediated Gene Therapy Halts Retinal Degeneration in PDE6β-deficient Dogs
Pichard, V., Provost, N., Mendes-Madeira, A., Libeau, L., Hulin, P., Tshilenge, K., Biget, M., Ameline, B., Deschamps, J., Weber, M., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.37 · Cited by 50
Pre-mRNA Processing Factors and Retinitis Pigmentosa: RNA Splicing and Beyond
Yang, C., Γεωργίου, Μ., Atkinson, R., Collin, J., Al-Aama, J. Y., Nagaraja‐Grellscheid, S., Johnson, C. A., Ali, R. R., Armstrong, L., Mozaffari‐Jovin, S., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.700276 · Cited by 49
Self-citationTransdermal optogenetic peripheral nerve stimulation
Maimon, B. E., Zorzos, A. N., Bendell, R., Harding, A., Fahmi, M., Srinivasan, S., Calvaresi, P., & Herr, H. M. (2017) · Journal of Neural Engineering · doi:10.1088/1741-2552/aa5e20 · Cited by 42
Hammadi, S., Tzoumas, N., Ferrara, M., Meschede, I. P., Lo, K., Harris, C., Lako, M., & Steel, D. H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082870 · Cited by 44
Jones, P. R., Yasoubi, N., Marko Nardini, A., & Rubin, G. S. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-20037 · Cited by 45
Self-citationIs the Eye an Extension of the Brain in Central Nervous System Disease?
Groef, L. D., & Cordeiro, M. F. (2017) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2016.0180 · Cited by 45
Holthaus, S.-M. K., Ribeiro, J., Abelleira, L. E., Pearson, R. A., Durán, Y., Georgiadis, A., Sampson, R. D., Rizzi, M., Hoke, J., Maswood, R. N., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.027 · Cited by 45
Self-citationRetinal Structure in RPE65-Associated Retinal Dystrophy
Kumaran, N., Georgiou, M., Bainbridge, J. W. B., Bertelsen, M., Larsen, M., Blanco-Kelly, F., Ayuso, C., Tran, H. V., Munier, F. L., Kalitzeos, A., et al. (2020) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.61.4.47 · Cited by 44
Self-citationSodi, A., Banfi, S., Testa, F., Corte, M. D., Passerini, I., Pelo, E., Rossi, S., Simonelli, F., & Italian IRD Working Group (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01868-4 · Cited by 44
The curious case of AAV immunology
Keeler, A. M., Zhan, W., Ram, S., Fitzgerald, K. A., & Gao, G. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.037 · Cited by 49
Metadata
- Authors
- Bainbridge, J. W. B., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., Georgiadis, A., Mowat, F. M., Beattie, S. G., Gardner, P. J., Feathers, K. L., Luong, V. A., Yzer, S., Balaggan, K., Viswanathan, A., de Ravel, T. J. L., Casteels, I., Holder, G. E., Tyler, N., Fitzke, F. W., Weleber, R. G., Nardini, M., Moore, A. T., Thompson, D. A., Petersen-Jones, S. M., Michaelides, M., van den Born, L. I., Stockman, A., Smith, A. J., Rubin, G., & Ali, R. R.
- Affiliations
- Moorfields Eye Hospital (GB)
- Michigan State University (US)
- University of Michigan (US)
- Rotterdam Eye Hospital (NL)
- Universitair Ziekenhuis Leuven (BE)
- Oregon Health & Science University (US)
- ORCID
- Bainbridge, James W.B.
- Sundaram, Venki
- Robbie, Scott J.
- Georgiadis, Anastasios
- Mowat, Freya M.
- Beattie, Stuart G.
- Yzer, Suzanne
- Balaggan, Kamaljit
- Viswanathan, Ananth
- Casteels, Ingele
- Holder, Graham E.
- Tyler, Nick
- Weleber, Richard G.
- Moore, Anthony T.
- Thompson, Debra A.
- Michaelides, Michel
- Smith, Alexander J.
- Rubin, Gary
- Ali, Robin R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-05-14
- Volume
- 372
- Issue
- 20
- Pages
- 1887-1897
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4497809
- OpenAlex
- W265142245
- Semantic Scholar
- 31832b3aa3500171fc5f2a951f0a4124bd40068d
- Cited by
- 743
- References
- 29
- Citations by year
- 2026: 36 · 2025: 36 · 2024: 46 · 2023: 44 · 2022: 63 · 2021: 92 · 2020: 81 · 2019: 68 · 2018: 79 · 2017: 97 · 2016: 72 · 2015: 27
- FWCI
- 39.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Durham Research Online (Durham University) (acceptedVersion)
- Durham Research Online (Durham University) (submittedVersion, cc-by)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Research to Prevent Blindness
- Wellcome Trust
- Massachusetts Medical Society
- National Institute for Health and Care Research (NF-SI-0507-10204, NF-SI-0513-10074, NIHR-RP-011-003)
- Sir Jules Thorn Charitable Trust
- University College London
- European Commission
- Ulverscroft Foundation
- Durham University
- KU Leuven
- Moorfields Eye Hospital NHS Foundation Trust
- Directorate for Biological Sciences
- Medical Research Council (MR/K024000/1, MR/M015815/1, MR/J005215/1)
- Engineering and Physical Sciences Research Council (EP/J017698/1, EP/J005193/1)
- Biotechnology and Biological Sciences Research Council (BB/M00211X/1)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- Leber congenital amaurosis, RPE65, gene therapy, retinal degeneration, visual function, retinal sensitivity, electroretinogram, vector dose, intraocular inflammation, visual acuity, canine model, species differences, long-term efficacy and safety
- MeSH terms
- Retinoid Isomerohydrolase, Dependovirus, Adolescent, Animals, Child, Disease Models, Animal, Dogs, Genetic Vectors, Humans, Mutation, Retina, Vision, Ocular, Genetic Therapy, DNA, Complementary, Disease Progression, cis-trans-Isomerases, Photoreceptor Cells, Vertebrate, Young Adult, Leber Congenital Amaurosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
